Skip to main content
. 2017 Sep 25;7:12261. doi: 10.1038/s41598-017-12434-z

Figure 3.

Figure 3

Pla2g3 −/− mice are protected against DSS-induced colitis. (a) Schematic representation of the procedure for DSS-induced colitis. (b,c) Daily monitoring of body weight loss (b) and clinical score (c) in Pla2g3 −/− and littermate Pla2g3 +/+ mice (8-week-old males) with or without DSS treatment (n = 16). (d,e) Gross appearance (d) and histology (e) of the colon in Pla2g3 +/+ and Pla2g3 −/− mice after treatment with DSS. Bar, 100 μm. (f) Scoring of proliferating CEC cells per section as determined by Ki67 staining of Pla2g3 +/+ and Pla2g3 −/− colons on day 4 (n = 3–5). (g) Quantitative RT-PCR of Pla2g3 and several inflammatory or epithelial barrier genes in the colon of Pla2g3 +/+ and Pla2g3 −/− mice after DSS treatment (n = 3–5). Mean ± SEM, *P < 0.05 and **P < 0.01. Data are from one experiment (f,g) or compiled from four experiments (b,c).